CMTRF Scientific Advisory Board

Charles Abrams, MD, PhD

University of Illinois, Chicago

Dr. Abrams is a physician-scientist at the University of Illinois Medical School in Chicago where he is head of the Neuromuscular Division. He received his master’s and doctoral degrees from Albert Einstein College of Medicine and trained in neurology at Cornell Medical Center and in neuromuscular medicine at Johns Hopkins University.

Dr. Abrams’s laboratory focuses on elucidating the mechanisms of the X-linked form of Charcot-Marie-Tooth disease and other related disorders. His work has been funded by the NIH, CMT Association and Muscular Dystrophy Association.

David Arnold, MD

University of Missouri

Since the Fall of 2022, Dr. Arnold has directed the NextGen Precision Health Initiative at the University of Missouri. NextGen Precision Health represents the largest research investment in the history of the University of Missouri system that aims to accelerate translational research discoveries to improve health outcomes. From 2009 to 2022, Dr. Arnold was on the faculty of The Ohio State University where he was a tenured full professor. As part of a multidisciplinary team at the Ohio State University and Nationwide Children’s Hospital, he was involved in the preclinical development and then the first-in-human gene therapy study for spinal muscular atrophy, a disorder that previously represented the most common genetic cause of death in infants. This life-saving treatment is now used internationally for spinal muscular atrophy (SMA).

Dr. Arnold was one of the first physiatrists in the country with accredited subspecialty training and board-certification in neuromuscular medicine. His preclinical and clinical research program is primarily focused on translational neuromuscular physiology in the context of health, aging, and disease and investigating the biology of aging as a unifying risk factor across diseases. Dr. Arnold’s clinical work is focused on genetic and acquired neuromuscular disorders.

Dr. Arnold holds a BS in Biology from Cumberland College and received his MD at the University of Louisville School of Medicine.

Anthony Antonellis, PhD

University of Michigan

Dr. Antonellis is a leading researcher in the field of peripheral nerve development and disease, and Professor and Chair of the Department of Human Genetics at the University of Michigan. The primary focus of his laboratory is elucidating the molecular mechanisms and pathways underlying Charcot-Marie-Tooth disease. Among his accomplishments in this area is the discovery of numerous mutations in tRNA synthetases that underly several forms of CMT.

Dr. Antonellis earned his Bachelor of Science degree from the University of Massachusetts, then after stints working at Genzyme Genetics and the Harvard Medical School, he went on to earn his PhD from the George Washington University and NIH Joint Program in Genetics. Before joining the faculty of the University of Michigan, Dr. Antonellis also completed a postdoctoral fellowship with the NIH National Human Genome Research Institute.

Paul August, PhD

ReviR Therapeutics

Dr. August is a scientific and business leader with extensive drug discovery experience within multiple therapeutic areas. He played a pivotal role in the advancement of the DTX CMT1A program through his advocacy efforts at the CMTRF. With an 18-year tenure at Sanofi, he demonstrated exceptional leadership of the Early to Candidate Unit and pioneered innovative rare disease research programs. He is a Co-founder of AcuraStem, a leader in the development of therapeutics for neurodegenerative diseases such as ALS, FTD and CMT. In his prior role at Agios Pharmaceuticals, he led the Genetically Defined Disease preclinical research efforts. Currently, Dr. August’s expertise is focused on Neuroscience and Oncology at ReviR Therapeutics. Primarily he is focused on the development of therapeutics to treat and prevent Huntington’s Disease.

Elisabetta Babetto, PhD

Ohio State University

Dr. Elisabetta Babetto is a Research Assistant Professor of Neurology at The Ohio State University, Wexner Medical Center. She studies the molecular and metabolic interactions of glia and axons after injury and in disease. Her work defined a novel instructive role of Schwann cells based on metabolic reprogramming to regulate the resistance of injured axons to degeneration. She brought Schwann cell metabolism to centerstage during axon degeneration and her laboratory continues to focus on the identification of axonal energetic demands and glia mechanisms of energy support after axotomy and in murine models of neurodegenerative conditions.

Dr. Babetto’s training in axon degeneration began when she was recruited by Dr. Michael Coleman in Cambridge, UK, where she graduated in 2010 with a PhD in Molecular Biology. Her graduate studies contributed to elucidating the mechanisms of action of the WldS protein, which confers a strong delay of axon degeneration after neuronal injury. She then joined the laboratory of Prof. Aaron DiAntonio at Washington University School of Medicine, St. Louis, MO, for postdoctoral training. During this time she discovered a novel pathway regulating axon survival, mediated by the E3 ubiquitin ligase Phr1, in mouse models of acute nerve injury.

Bruce Carter, PhD

Vanderbilt University

Dr. Carter is Professor of Biochemistry and Associate Director of the Brain Institute at Vanderbilt University. After completing his bachelor’s degree at Alma College, he obtained his PhD in Biological Chemistry from the University of Michigan. He did postdoctoral training with Yves Barde at the Max Plank Institute in Munich, Germany and with Moses Chao at Cornell Medical School.

In 1997 Dr. Carter joined the Department of Biochemistry at Vanderbilt University School of Medicine. His research focuses on the mechanisms by which neurotrophins regulate cell death in the developing peripheral nervous system as well as the mechanisms underlying Schwann cell development and dysregulation, including in models of CMT.

Jesse M. Cedarbaum, MD

Coeruleus Clinical Sciences LLC

Dr. Cedarbaum obtained his medical degree from Yale Medical School, where he is currently Professor (Adjunct) of Neurology. After residency at New York Hospital-Cornell Medical Center Dr. Cedarbaum joined the Cornell faculty and led the Parkinson and Movement Disorders program at Burke Rehabilitation Center and the New York Hospital, from 1983-1990. Dr. Cedarbaum then joined Regeneron, where he led the establishment of the clinical development function and served as Program Director and later Vice President of Clinical Affairs from 1990-2007.  He subsequently held positions at Elan, Cytokinetics, and Bristol-Myers Squib and most recently as Sr. Distinguished Investigator at Biogen, leading a team focused on development of novel therapeutics for Parkinson’s disease and Movement Disorders.  Dr. Cedarbaum has authored or co-authored over 100 peer-reviewed scientific publications, most in the area of neurotherapeutics.  He is a Fellow of both the American Academy of Neurology and the American Neurological Association.

Amanda Haidet-Phillips, PhD

Sarepta Therapeutics

Dr. Haidet-Phillips leads cross-functional program teams at Sarepta to bring gene therapies from the laboratory to patients. Prior to Sarepta, Dr. Haidet-Phillips worked in pharma and biotech as part of AveXis and then Novartis Institute for BioMedical Research to help transition gene therapy products from the pre-clinical proof of concept stage in R&D to first-in human trials.

Prior to joining industry, Dr. Haidet-Phillips served as Scientific Portfolio Director for the Muscular Dystrophy Association where she led the strategic management of research grants and investments focused on Charcot-Marie-Tooth Disease, Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, and Myasthenia Gravis. Dr. Haidet-Phillips completed a post-doctoral fellowship at Johns Hopkins University seeking to understand the causes of ALS and develop new therapeutic approaches for the disease. She received her Ph.D from The Ohio State University where she helped to develop gene therapies for neuromuscular disease.

Corey R. Hopkins, PhD

University of Nebraska Medical Center

Dr. Corey Hopkins has more than 20 years of experience in both the pharmaceutical industry and academic drug discovery. He was a project team leader at Sanofi Pharmaceuticals, where he led projects that resulted in two clinical candidate designations. Dr. Hopkins then moved to the Vanderbilt Center for Neuroscience Drug Discovery, where he was responsible for multiple projects that were licensed to industrial partners and directly led to a compound being advanced into clinical trials.

Since joining UNMC in 2016, Dr. Hopkins has had one project licensed and has had two patents granted. Under his direction, the newly launched UNMC Center for Drug Design and Innovation will bridge the gap between drug discovery and drug development, promoting a new “mixed model” of drug discovery has seen a dramatic increase in partnerships between biotechnology companies and the traditional large pharma companies. Dr. Hopkins holds a B.S. in Chemistry from Indiana University and earned his Ph.D., at the University of Pittsburgh. 

Marina Kennerson, PhD

ANZAC Research Institute and Sydney Medical School

Dr. Kennerson is a Professor of Neurogenetics with the ANZAC Research Institute and Sydney Medical School, University of Sydney, Australia. She received her Bachelor of Science (Hons) degree from University of New South Wales and PhD from the University of Sydney. Her scientific training included mapping genes for inherited neurodegenerative diseases and using genomic technologies to identify gene mutations. It is through her training that Dr. Kennerson was introduced to CMT and she has continued to contribute to this field of research.

Dr. Kennerson heads the Gene Discovery and Translational Genomics Inherited Peripheral Neuropathies Program at the ANZAC Research Institute. Her team has discovered several neuropathy genes and is doing pioneering research to discover the role of structural variation mutations causing gene dysregulation as a new disease mechanism for hereditary neuropathies. Her research program includes functional studies for recent gene (ATP7A and PDK3) and SV mutation (CMTX3 and DHMN1) discoveries using induced pluripotent stem cell derived motor neurons and animal models (C. elegans and mouse).

Dr. Kennerson enjoys teaching and has run international linkage, bioinformatics and next generation sequencing courses at Sultan Qaboo University, Oman, Cold Spring Harbor Laboratories, USA and the University of Malaya, Malaysia and is the Genetics Unit of Study Co-ordinator for the Masters Postgraduate Program at the Brain and Mind Centre, Sydney. Dr. Kennerson is the Scientific Secretariat of the Asian Oceanic Inherited Neuropathy Consortium (AOINC) and a member of the International Charcot-Marie-Tooth and Related Neuropathies Consortium (CMTR) Board.

Cat Lutz, PhD, MBA

The Jackson Laboratory

Cat Lutz, Ph.D., M.B.A. is the Vice President of the Rare Disease Translational Center at The Jackson Laboratory (JAX). With 25 years of experience in mouse genetics, Dr. Lutz has focused her research efforts on patient organizations and families diagnosed with rare diseases. The JAX Rare Disease Translational Center incorporates precision mouse models and broad-based drug efficacy testing to support IND enabling studies. She serves as the Principal Investigator of multiple NIH sponsored programs including the Center for Precision Genetics, The Somatic Cell Genome Editing Center, and Mouse Mutant Research and Resource Center. As a neuroscientist by training, Dr. Lutz has worked on models of the central nervous system such as Spinal Muscular Atrophy, Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia. Dr. Lutz was recently awarded a 2021 Rare Impact Award by the National Organization for Rare Disorders.

Brett McCray, MD, PhD

University of Michigan

Brett A. McCray, MD, PhD, is a physician scientist with training in neuromuscular disease and a background in cellular and molecular neuroscience. He is currently an Assistant Professor in Neurology at the University of Michigan. He received his MD and PhD degrees from the University of Pennsylvania where he worked with Dr. J. Paul Taylor on the pathogenesis of hereditary neuropathy due to mutations in Rab7. He then completed neurology residency at the Mass General-Brigham Neurology program, followed by neuromuscular fellowship at Johns Hopkins. In addition to caring for patients with CMT and other neuromuscular diseases, he also runs a basic science and translational laboratory focused on inherited forms of peripheral neuropathy. His laboratory research is primarily focused on the pathogenesis of Charcot-Marie-Tooth disease type 2C (CMT2C) and related disorders that are caused by gain-of-function mutations in the cation channel TRPV4. His laboratory studies cellular and animal models to gain insight into the role of TRPV4 in health and disease. He has also established a TRPV4 patient registry and specialized multidisciplinary natural history study to better define the course of the disease and to lay the foundation for a future clinical trial.

Kelly Monk, PhD

Vollum Institute, Oregon Health and Sciences University

Dr. Monk is a senior scientist and co-director of the Vollum Institute. After earning her B.S. degree in Biochemistry from Elmira College in 2001, Dr. Monk pursued doctoral studies at the University of Cincinnati/Cincinnati Children’s Hospital under the mentorship of Nancy Ratner and was awarded her Ph.D. in Cell Biology in 2006. She did postdoctoral training in the lab of William Talbot at Stanford University School of Medicine. In 2011, she was appointed as an assistant professor in the Department of Developmental Biology at Washington University School of Medicine in St. Louis, and was promoted to associate professor with tenure in 2016. Dr. Monk joined the Vollum Institute as co-director and full professor in 2017 and was named director of the Vollum/OHSU Neuroscience Graduate Program in 2018.

 Dr. Monk began her independent career in 2011 and has since gained recognition as a leader in the fields of glial cell biology and neuron-glial interactions. Her work on Gpr126 and other aGPCRs has helped to lay the foundation for the rapidly growing aGPCR field. She and her team have discovered new roles for aGPCRs in the developing nervous system, were the first to delineate aGPCR functions in the adult nervous system during homeostasis and injury, and defined new activation paradigms, ligands, and downstream signaling mechanisms for this previously completely enigmatic receptor class. Beyond aGPCRs, she has leveraged the power of zebrafish genetics coupled with synergistic approaches in mouse, and her group is now armed with ~30 mutants from new forward genetic screens that can address key outstanding questions in glial cell biology and neuroscience including: glial fate specification and heterogeneity; the cell biology of myelination; mechanisms of glial-neuron and glial-glial interactions; glial support of neurons; and the contribution of glia to circuits and behavior.

William Motley, MD, PhD

Rapport Therapeutics

Bipasha Mukherjee-Clavin, MD, PhD

Johns Hopkins Neurology

Dr. Bipasha Mukherjee-Clavin (bee-PAA-sha MOOK-er-jee CLAY-vin) co-directs the Johns Hopkins Charcot-Marie-Tooth multi-disciplinary clinic and is the incoming site PI for the Inherited Neuropathies Consortium international CMT natural history studies. As a stem cell biology-trained physician-scientist, Dr. Mukherjee-Clavin’s research is focused on the use of patient-derived induced pluripotent stem cells to model genetic Schwann cell and peripheral nerve disorders to undercover novel pathways and potential treatments. 

 Dr. Mukherjee-Clavin completed her undergraduate studies at the University of California, Berkeley, followed by pre-doctoral research at the University of California, San Francisco.  She then completed her MD/PhD degrees, Neurology residency, and clinical Neuromuscular fellowship in the Johns Hopkins University School of Medicine.  She joined the Johns Hopkins Neurology faculty in 2022. 

Alexander Rossor, MD, PhD

UCL Queen Square Institute of Neurology

Dr. Rossor is an honorary consultant neurologist and Wellcome Trust Post-Doctoral Clinical Fellow at the UCL Queen Square Institute of Neurology and the National Hospital for Neurology and Neurosurgery, London, United Kingdom. He earned his doctor of medicine degree, graduating with distinction from the University of Newcastle upon Tyne, where he has was also awarded the Goyder Memorial Scholarship and Luke Armstrong Prize in pathology. He undertook specialist neurology training in London, completing a doctorate on Charcot-Marie-Tooth disease with Professor Mary Reilly at the UCL Queen Square Institute of Neurology.

Dr. Rossor currently works as a clinician-scientist at the UCL Queen Square Institute of Neurology in the laboratory of Professor Giampietro Schiavo, researching the role of receptor trafficking in forms of hereditary motor neuropathy. He is also the hospital board representative for the European Reference Network for Rare Neuromuscular Diseases and is an associate editor of the Journal of the Peripheral Nerve Society.